Showing results (71-80 of 367) with videos related to
Sort By:
Pageof 37
British Journal of Hospital Medicine|October 2, 1996
Advances in clinical pharmacology and therapeutics: endothelinD E Newby, D J WebbClinical Pharmacology and Therapeutics|November 1, 1995
S-mephenytoin hydroxylation phenotypes in a Jordanian populationH F Hadidi, Y M Irshaid, R L Woosley, et al.The Pharmacogenomics Journal|May 1, 2013
Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependentV Michaud, Y Kreutz, T Skaar, et al.Journal of Chromatography. B, Biomedical Sciences and Applications|September 19, 2000
Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic studyZ Desta, N V Soukhova, A Morocho, et al.Proceedings of the National Academy of Sciences of the United States of America|October 1, 1977
In vivo and in vitro phosphorylation of rat liver fructose-1,6-bisphosphataseJ P Riou, T H Claus, D A Flockhart, et al.Journal of Clinical Psychopharmacology|December 24, 1998
Prolongation of QT interval in isolated feline hearts by antipsychotic drugsM D Drici, W X Wang, X K Liu, et al.British Journal of Clinical Pharmacology|June 1, 1989
The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteersD J Webb, N Benjamin, P VallanceBritish Journal of Clinical Pharmacology|May 3, 2000
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancerM L Williams, P Bhargava, I Cherrouk, et al.Clinical Pharmacology and Therapeutics|January 1, 1999
Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindroneC B Trapnell, S R Donahue, J M Collins, et al.Clinical Pharmacology and Therapeutics|February 10, 2012
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteersV Michaud, E Ogburn, N Thong, et al.Pageof 37